Skip to content

Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

Clinical Evaluation of the Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05519007
Enrollment
936
Registered
2022-08-29
Start date
2023-09-26
Completion date
2026-12-31
Last updated
2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Joint Infection

Brief summary

A prospective, single-site, double-arm, parallel, interventional, randomized, controlled clinical trial to assess 90-day rate of joint infections in subjects undergoing primary hip replacements after administration of Next Science No-Rinse Solution (hereby referred to as NS) vs SOC (saline irrigation). The Next Science treatment arm will exhibit greater reduction in rate of 90-day post-operative joint infection than SOC (saline) arm

Interventions

OTHERNo-Rinse Solution (NS)

The surgical site will be irrigated with NS prior to closure,

The surgical site will be irrigated with Saline

Sponsors

Next Science TM
CollaboratorINDUSTRY
Northwell Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

1. Adult that meets at least one of the below criteria at time of screening: * American Society of Anesthesiologists (ASA) 3 2 * BMI \>35 * Patient with functional limitations as a result of disease1: * Poorly treated hypertension * Poorly treated diabetes * Chronic renal failure * Bronchospastic disease * Disease with intermittent exacerbations * Stable angina * Implanted pacemaker * Known history as an active nicotine use (smoker) * Known history of uncontrolled diabetes mellitus (HgbA1C \> 7.0) * Known history of end stage organ disease * Known history of inflammatory arthritis and currently on rheumatological medication (DMARDs) * Known history of current active cancer treatment (chemotherapy) * Venous Disease (Surgical Risk Calculator from ACS-NSQIP) * Charleston Comorbidity Score \> 2 * Elixhauser Score \>11 * Age 65 or older 2. Subject is scheduled to primary joint replacement. 3. Subject is willing and able to comply with all study procedures including transportation to the study site for all scheduled visits and be available for the duration of the study. 4. Subject has understood, signed, and dated the informed consent form.

Exclusion criteria

1. Unable to provide signed and dated informed consent. 2. Unable or unwilling to comply with all study-related procedures. 3. Known history of allergic reaction to any of the study products or its components, including any products used for standard of care (such as dressings or any coverings) 4. Subject has contraindications to general anesthesia 5. Any subject positive for Covid-19 virus at time of surgical screening 6. Subjects have evidence of prolonged QT segment, per EKG. 7. Subjects from a vulnerable population, in accordance with 45 CFR 46 Subparts B, C, and D

Design outcomes

Primary

MeasureTime frameDescription
infection rateat 90 daysJoint infection rate after surgery

Secondary

MeasureTime frameDescription
QT prolongationup to 24 hours (from the time of irrigation to closure)Incidences of QT prolongation and short-term hypocalcemia

Countries

United States

Contacts

Primary ContactMeriton Ruhani
ruhanimeriton@gmail.com(212)434-4724

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026